Upstream Bio, Inc.
NASDAQ:UPBBiotechnology
+$0.10 today
- Market cap
- $114.01M
- Beta
- 1.11
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$2.89
Volume 1.24M
Average 0.66M
UPB Total Non-current Assets
All assets not expected to be converted to cash within one year.
Upstream Bio, Inc.NASDAQ: UPB
Total Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Total non-current assets falls 25.5% from a year ago
Total non-current assets stood at $1.78M at the end of Q1 FY2026, down 25.5% from a year earlier and down 10.1% from the prior quarter. Over 3 fiscal years it compounded at +126.0% a year.
Context
- Total non-current assets amounted to 0.6% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Total non-current assets increased in 2 of the last 3 fiscal years.
What to watch
Whether total non-current assets keeps falling in the next quarterly balance sheet after a -25.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 1.98M USD
- Year-over-year change
- -22.8%
- 3-year CAGR
- +126.0%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.98M | -22.8% |
| FY2024 | 2024-12-31 | 2.56M | +1166.8% |
| FY2023 | 2023-12-31 | 202K | +18.1% |
| FY2022 | 2022-12-31 | 171K | — |
Total Non-current Assets vs competitors
How UPB compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -25.5% is the 5th highest of 9, against a peer median of -22.7%.
- Total non-current assets amounts to 0.6% of total assets for UPB, versus a peer median of 2.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $292.33M USD | -32.8% | +1.2% | 38.5% | |
| Mar 2026 | $192.35M USD | -54.7% | -29.1% | 18.4% | |
| Jun 2026 | $39.38M USD | -18.7% | -18.8% | 4.1% | |
| Mar 2026 | $22.27M USD | -26.7% | -20.9% | 3.8% | |
| Mar 2026 | $17.52M USD | +9.8% | +74.3% | 2.3% | |
| Sep 2026 | $7.94M USD | -15.2% | -1.3% | 1.0% | |
| Sep 2026 | €1.86M EUR | +8.6% | +37.2% | 0.6% | |
UPBUpstream Bio, Inc. | Mar 2026 | $1.78M USD | -25.5% | +126.0% | 0.6% |
| Mar 2026 | $1.49M USD | -98.4% | -39.8% | 0.3% | |
| Sep 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding UPB) | — | -22.7% | -10.0% | 2.3% | |
Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Upstream Bio, Inc.
NASDAQ:UPB
Intrinsic Alpha fair value
Locked
Current Price
$2.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.